Press releases

Regulatory

December 11, 2017

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Regulatory

December 1, 2017

Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2017

Regulatory

November 30, 2017

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000

Regulatory

October 4, 2017

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer

Regulatory

October 2, 2017

Nexttobe Extends Loan to Oasmia Pharmaceutical

Regulatory

September 29, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

September 25, 2017

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2017

Regulatory

September 21, 2017

Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting

Regulatory

September 11, 2017

Notification from Oasmia Pharmaceutical AB

Regulatory

September 1, 2017

Oasmia Pharmaceutical AB (publ)

Regulatory

August 31, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

August 25, 2017

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

Regulatory

August 8, 2017

Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

Regulatory

July 31, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

July 7, 2017

Oasmia Pharmaceutical AB (publ) announces result of the rights issue

Regulatory

July 7, 2017

The Oasmia Pharmaceutical Annual Report is now published

Regulatory

June 21, 2017

Issuance of warrants in Oasmia Pharmaceutical AB (publ)

Regulatory

June 19, 2017

Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue

Regulatory

June 14, 2017

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Regulatory

June 12, 2017

Oasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEK

Regulatory

June 8, 2017

Oasmia Pharmaceutical AB (publ) replaces current convertible loan with new debt

Regulatory

June 8, 2017

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2016 – April 30, 2017

Regulatory

June 2, 2017

Report from extra general meeting 2 June 2017

Regulatory

May 31, 2017

Number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

May 29, 2017

Oasmia Pharmaceutical Issues Clarification Regarding Clinical Study OAS-12DOC-BIO

Regulatory

May 23, 2017

Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm on June 15th

Regulatory

May 10, 2017

Oasmia convenes an extraordinary general meeting on 2 June, 2017

Regulatory

May 10, 2017

Oasmia Pharmaceutical to spin-off veterinary assets

Regulatory

May 1, 2017

Increased number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

April 25, 2017

Conversion of SEK 42M convertible loan in Oasmia

Regulatory

April 18, 2017

Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00

Regulatory

March 31, 2017

Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95

Regulatory

March 30, 2017

Oasmia evaluates the possibility to carry out a private placement of new convertible instruments

Regulatory

March 21, 2017

Oasmia intends to issue convertible to replace current convertible loan

Regulatory

March 3, 2017

Interim report for the period May 2016 – January 2017

Regulatory

March 1, 2017

Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors

Regulatory

February 28, 2017

Oasmia Pharmaceuticals Chairman Anders Lönner Resigns

Regulatory

January 23, 2017

Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division